Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Hookipa Pharma has raised $14.4M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2023.
Hookipa Pharma's investors include Hillhouse Investment, Gilead Sciences, Samsara BioCapital, Redmile Group, Sofinnova Partners.
Hookipa Pharma is headquartered in New York, United States.
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Hookipa Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hookipa Pharma — Funding & Investors." VCBacked, December 21, 2023, https://www.vcbacked.co/company/hookipa-pharma. Accessed November 11, 2026.
VCBacked. (2023). Hookipa Pharma — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/hookipa-pharma
{{cite web |title=Hookipa Pharma — Funding & Investors |url=https://www.vcbacked.co/company/hookipa-pharma |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Hookipa Pharma? Request a listing update